ID   C6TK-
AC   CVCL_5H90
DR   Wikidata; Q54808232
RX   PubMed=4842353;
RX   PubMed=6165598;
CC   Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Transformant: ChEBI; CHEBI:50102; N-methyl-N-nitrosourea (NMU).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
CC   Breed/subspecies: Wistar Furth.
DI   NCIt; C64069; Rat malignant glioma
OX   NCBI_TaxID=10116; ! Rattus norvegicus (Rat)
HI   CVCL_0194 ! C6
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 7
//
RX   PubMed=4842353; DOI=10.1016/0014-4827(74)90737-X;
RA   Schimmer B.P., Stevenson L.F., ter Hofstede C., Cheung N.H., Marks A.;
RT   "Glial tumor cells deficient in thymidine kinase: isolation and
RT   characterization.";
RL   Exp. Cell Res. 86:425-428(1974).
//
RX   PubMed=6165598; DOI=10.1016/0014-4827(81)90332-3;
RA   McMorris F.A., Miller S.L., Pleasure D.E., Abramsky O.;
RT   "Expression of biochemical properties of oligodendrocytes in
RT   oligodendrocyte x glioma cell hybrids proliferating in vitro.";
RL   Exp. Cell Res. 133:395-404(1981).
//